Dyrk1A induces pancreatic β cell mass expansion and improves glucose tolerance

Type 2 diabetes is caused by a limited capacity of insulin-producing pancreatic β cells to increase their mass and function in response to insulin resistance. The signaling pathways that positively regulate functional β cell mass have not been fully elucidated. DYRK1A (also called minibrain/MNB) is a member of the dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) family. A significant amount of data implicates DYRK1A in brain growth and Down syndrome, and recent data indicate that Dyrk1A haploinsufficient mice have a low functional β cell mass. Here we ask whether Dyrk1A upregulation could be a way to increase functional β cell mass. We used mice overexpressing Dyrk1A under the control of its own regulatory sequences (mBACTgDyrk1A). These mice exhibit decreased glucose levels and hyperinsulinemia in the fasting state. Improved glucose tolerance is observed in these mice as early as 4 weeks of age. Upregulation of Dyrk1A in β cells induces expansion of β cell mass through increased proliferation and cell size. Importantly, mBACTgDyrk1A mice are protected against high-fat-diet-induced β cell failure through increase in β cell mass and insulin sensitivity. These studies show the crucial role of the DYRK1A pathway in the regulation of β cell mass and carbohydrate metabolism in vivo. Activating the DYRK1A pathway could thus represent an innovative way to increase functional β cell mass.

[1]  N. L. Le Douarin.  On the origin of pancreatic endocrine cells. , 1988, Cell.

[2]  N. Douarin.  On the origin of pancreatic endocrine cells , 1988, Cell.

[3]  P. Rorsman,et al.  The pancreatic beta-cell as a fuel sensor: an electrophysiologist's viewpoint , 1997, Diabetologia.

[4]  R. Scharfmann,et al.  Expression of Neuronal Traits in Pancreatic Beta Cells , 1997, The Journal of Biological Chemistry.

[5]  M. Permutt,et al.  Islet beta cell expression of constitutively active Akt1/PKB alpha induces striking hypertrophy, hyperplasia, and hyperinsulinemia. , 2001, The Journal of clinical investigation.

[6]  M. Permutt,et al.  Islet β cell expression of constitutively active Akt1/PKBα induces striking hypertrophy, hyperplasia, and hyperinsulinemia , 2001 .

[7]  X. Estivill,et al.  Dyrk1A Haploinsufficiency Affects Viability and Causes Developmental Delay and Abnormal Brain Morphology in Mice , 2002, Molecular and Cellular Biology.

[8]  James D. Johnson,et al.  Increased islet apoptosis in Pdx1+/- mice. , 2003, The Journal of clinical investigation.

[9]  R. Scharfmann,et al.  Role for VPAC2 receptor-mediated signals in pancreas development. , 2003, Diabetes.

[10]  James D. Johnson,et al.  Defective insulin secretion and increased susceptibility to experimental diabetes are induced by reduced Akt activity in pancreatic islet beta cells. , 2004, The Journal of clinical investigation.

[11]  J. Neilson,et al.  Calcineurin/NFAT signalling regulates pancreatic beta-cell growth and function. , 2006, Nature.

[12]  J. Neilson,et al.  Calcineurin/NFAT signalling regulates pancreatic β-cell growth and function , 2006, Nature.

[13]  M. Gambello,et al.  Disruption of Tsc2 in pancreatic β cells induces β cell mass expansion and improved glucose tolerance in a TORC1-dependent manner , 2008, Proceedings of the National Academy of Sciences.

[14]  C. Sempoux,et al.  Pancreatic β‐cell mass in European subjects with type 2 diabetes , 2008, Diabetes, obesity & metabolism.

[15]  E. Ferrannini.  The stunned beta cell: a brief history. , 2010, Cell metabolism.

[16]  James D. Johnson,et al.  Transgenic Overexpression of Active Calcineurin in β-Cells Results in Decreased β-Cell Mass and Hyperglycemia , 2010, PloS one.

[17]  M. Palassini,et al.  Derepression of Polycomb targets during pancreatic organogenesis allows insulin-producing beta-cells to adopt a neural gene activity program. , 2010, Genome research.

[18]  M. Lequin,et al.  Distinctive Phenotypic Abnormalities Associated with Submicroscopic 21q22 Deletion Including DYRK1A , 2010, Molecular Syndromology.

[19]  C. Wright,et al.  Context-specific α- to-β-cell reprogramming by forced Pdx1 expression. , 2011, Genes & development.

[20]  F. Tejedor,et al.  MNB/DYRK1A as a multiple regulator of neuronal development , 2011, The FEBS journal.

[21]  M. Tatar,et al.  Minibrain/Dyrk1a Regulates Food Intake through the Sir2-FOXO-sNPF/NPY Pathway in Drosophila and Mammals , 2012, PLoS genetics.

[22]  R. Scharfmann,et al.  l-Leucine Alters Pancreatic β-Cell Differentiation and Function via the mTor Signaling Pathway , 2012, Diabetes.

[23]  Y. Hérault,et al.  DYRK1A: A master regulatory protein controlling brain growth , 2012, Neurobiology of Disease.

[24]  F. Ashcroft,et al.  Diabetes Mellitus and the β Cell: The Last Ten Years , 2012, Cell.

[25]  D. Drucker.  Incretin Action in the Pancreas: Potential Promise, Possible Perils, and Pathological Pitfalls , 2013, Diabetes.

[26]  Ruedi Aebersold,et al.  Dual Specificity Kinase DYRK3 Couples Stress Granule Condensation/Dissolution to mTORC1 Signaling , 2013, Cell.

[27]  M. Castelo‐Branco,et al.  Triplication of DYRK1A causes retinal structural and functional alterations in Down syndrome. , 2013, Human molecular genetics.

[28]  O. Manzoni,et al.  Prefrontal Deficits in a Murine Model Overexpressing the Down Syndrome Candidate Gene Dyrk1a , 2014, The Journal of Neuroscience.

[29]  R. Scharfmann,et al.  Dyrk1a haploinsufficiency induces diabetes in mice through decreased pancreatic beta cell mass , 2014, Diabetologia.

[30]  Changhong Li,et al.  Pdx1 maintains β cell identity and function by repressing an α cell program. , 2014, Cell metabolism.

[31]  James D. Johnson,et al.  Transgenic overexpression of active calcineurin in beta-cells results in decreased beta-cell mass and hyperglycemia , 2015 .